What is HC Wainwright’s Forecast for RIGL Q3 Earnings?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Research analysts at HC Wainwright issued their Q3 2026 earnings estimates for Rigel Pharmaceuticals in a research report issued on Wednesday, March 4th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings per share of $1.27 for the quarter. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q4 2026 earnings at $1.30 EPS and FY2026 earnings at $4.73 EPS.

A number of other research analysts have also commented on the stock. Wall Street Zen raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a report on Thursday, January 22nd. Zacks Research upgraded Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 18th. Finally, Citigroup reiterated a “buy” rating on shares of Rigel Pharmaceuticals in a research report on Wednesday, January 14th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Rigel Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $45.67.

Rigel Pharmaceuticals Stock Performance

NASDAQ RIGL opened at $28.87 on Friday. The company’s fifty day moving average is $36.85 and its two-hundred day moving average is $37.24. Rigel Pharmaceuticals has a 52-week low of $15.50 and a 52-week high of $52.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.42 and a quick ratio of 2.14. The firm has a market capitalization of $533.23 million, a price-to-earnings ratio of 1.53 and a beta of 1.10.

Institutional Trading of Rigel Pharmaceuticals

Large investors have recently bought and sold shares of the stock. AlphaQuest LLC raised its stake in Rigel Pharmaceuticals by 234.8% during the third quarter. AlphaQuest LLC now owns 1,105 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 775 shares in the last quarter. Laurel Wealth Advisors LLC boosted its stake in shares of Rigel Pharmaceuticals by 1,773.3% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 2,810 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 2,660 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of Rigel Pharmaceuticals in the 3rd quarter worth about $55,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Rigel Pharmaceuticals by 400.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,275 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 1,020 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Rigel Pharmaceuticals during the 3rd quarter worth about $62,000. 66.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Rigel Pharmaceuticals

In other news, Director Walter H. Moos sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $36.36, for a total value of $145,440.00. Following the sale, the director directly owned 12,722 shares in the company, valued at approximately $462,571.92. This represents a 23.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 9.48% of the company’s stock.

Trending Headlines about Rigel Pharmaceuticals

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright sharply raised its FY2026 EPS forecast to $4.73 from $3.14, signaling much stronger near-term profitability expectations that could support higher valuation if realized.
• Neutral Sentiment: HC Wainwright published detailed quarterly 2026 forecasts (Q1: $0.95, Q2: $1.20, Q3: $1.27, Q4: $1.30) that provide a clear earnings cadence for the year but reflect forward modeling assumptions investors should verify against company guidance and pipeline progress.
• Neutral Sentiment: The company’s recent earnings call transcript offers management commentary and operational detail investors should review to reconcile analyst projections with product, revenue and margin drivers. Rigel Pharma (RIGL) Earnings Call Transcript
• Negative Sentiment: Rigel disclosed significant uncertainty around pursuing FDA fast-track designation for its programs, which raises regulatory execution risk that could delay approvals or returns and pressure the stock. Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).